ライフサイエンスコーパス: be approved for

1 The oral agents are approved for 1-2 years of therapy, but treatment is

2 ular resistance [PVR] >/=240 dynes.s.cm) who were approved for a POPH MELD exception between 2006 and

3 Four antibiotics were approved for acute bacterial skin and skin-structur

4 rials, and the mTOR-inhibitor everolimus has been approved for advanced or metastatic aromatase inhib

5 Tamoxifen has been approved for breast cancer risk reduction in high-r

6 ogenic drugs targeting VEGF or its receptors are approved for cancer treatment.

7 wth factor (VEGF) and its receptors (VEGFRs) are approved for cancer treatment.

8 r (EGFR)/ERBB1, or a co-receptor, HER2, have been approved for cancer therapy.

9 ersons 2 through 49 years of age but has not been approved for children under 2 or asthmatics due to

10 -oral, direct-acting antiviral regimens have been approved for children with chronic hepatitis C viru

11 or children >7 years of age, and oseltamivir is approved for children >1 year of age.

12 Zanamivir is approved for children >7 years of age, and oseltamivi

13 Extended-release guanfacine is approved for children with attention deficit hyperact

14 several molecularly targeted therapies have been approved for clear cell renal cell carcinoma (ccRCC

15 As a variety of antimuscarinic drugs are approved for clinical use against other conditions,

16 and cost-efficiently investigate drugs that are approved for clinical use in the treatment of anothe

17 nce high-sensitivity cardiac troponin assays are approved for clinical use in the United States.

18 c acid (SAHA) is the first HDAC inhibitor to be approved for clinical use as an anticancer agent.

19 he first orally active inhibitor of renin to be approved for clinical use as an antihypertensive agen

20 first targeted tyrosine kinase inhibitor to be approved for clinical use, and remains first-line the

21 At present just one IRE system has been approved for clinical use and is currently commerci

22 To date, two ROCK inhibitors have been approved for clinical use in Japan (fasudil and rip

23 tive inhibitor of the 26S proteasome and has been approved for clinical use in the treatment of relap

24 ome these limitations, only one compound has been approved for clinical use so far.

25 nt that specifically targets B cells has yet been approved for clinical use, all existing disease-mod

26 agonists have been developed, none have yet been approved for clinical use, based on inadequate effi

27 eads in preclinical models, no agent has yet been approved for clinical use.

28 eless, no effective AP-1 inhibitors have yet been approved for clinical use.

29 activity versus one or multiple kinases have been approved for clinical use.

30 rol ester transfer protein inhibitor has yet been approved for clinical use.

31 , not a single phosphatase inhibitor has yet been approved for clinical use.

32 Several therapeutic nanocarriers have been approved for clinical use.

33 w of time has passed since a new Pt drug has been approved for clinical use.

34 Because sildenafil is approved for clinical use, our results suggest that a

35 Several new drugs have been approved for CLL treatment (fludarabine, bendamusti

36 , no vaccines or antiviral therapeutics have been approved for combating DENV-associated disease.

37 patients who were prescribed a PCSK9i, 47.0% were approved for coverage by the payer.

38 le record according to CPRD quality control, were approved for CPRD and Hospital Episodes Statistics

39 ealth and no vaccines or antiviral therapies are approved for dengue fever.

40 Based on the results of recent studies, PRK is approved for designated Naval aviators and flight off

41 It has already been approved for destination therapy of heart failure,

42 Targeted treatments that are approved for differentiated and medullary thyroid ca

43 get through each step of the evaluation and be approved for donation.

44 No effective vaccine or treatment has yet been approved for either virus.

45 ble EGFR tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation-p

46 noma (HNSCC), where EGFR-blocking antibodies are approved for first-line treatment.

47 ptor tyrosine kinase inhibitor sunitinib has been approved for first-line treatment of patients with

48 The DAA-containing regimens are approved for HCV genotype 1 infection in HCV treatme

49 of histone deacetylation or DNA methylation are approved for hematological malignancies by the US Fo

50 abuvir (OBV/PTV/r + DSV) +/- ribavirin (RBV) is approved for hepatitis C virus (HCV) genotype 1 (GT1)

51 with up to 90% lethality, and no treatments are approved for human use.

52 , have only recently been reported, and none are approved for human use.

53 To date, no vaccine or treatments are approved for human use.

54 of NF-kappaB ligand (RANKL)-blocking Ab has been approved for human use in potentially millions of o

55 icotine in animals, but these drugs have not been approved for human use.

56 isease vaccine based on recombinant OspA has been approved for human use.

57 SAHA is approved for human use, and molecules similar to JQ1

58 Since the first murine monoclonal antibody was approved for human therapeutic use over a decade ago

59 The first therapeutic aptamer was approved for human use in 2004, and a range of chemi

60 omography (PET)/computed tomography (CT) has been approved for imaging in many malignancies but not f

61 e Melody transcatheter pulmonary valve (TPV) was approved for implantation in obstructed right ventri

62 arby canine kidney 33016-PF cell line, which is approved for influenza vaccine manufacture.

63 grated in the brain-spine interface have all been approved for investigational applications in simila

64 and social morbidity, but no pharmacotherapy is approved for its treatment in the United States.

65 elve of the species found are listed or have been approved for listing in 2017 in the appendices of t

66 late was the first new oral anticoagulant to be approved for long-term anticoagulant treatment in 6 d

67 rlistat, a pancreatic lipase inhibitor, have been approved for long-term obesity treatment.

68 ide effects, and none of the drugs evaluated is approved for maintenance therapy.

69 Very few medications are approved for management of type 2 diabetes in youth.

70 In 2001, alemtuzumab was approved for marketing in the United States and Euro

71 bitor targeting MET in addition to VEGFR and is approved for medullary thyroid cancer.

72 No therapeutics or vaccines are approved for MERS; thus, development of novel therap

73 Although immunotherapies are approved for MIBC, the majority of patients fail to

74 Many new-generation AEDs have not been approved for monotherapy, causing drug labelling an

75 To date, no pharmacological treatment is approved for NAFLD/NASH.

76 Only four new chemical entities were approved for neglected diseases (three for malaria,

77 GM-CSF (sargramostim) is approved for neutropenia associated with stem cell tr

78 eted tyrosine kinase inhibitor, has recently been approved for nonadipocytic soft tissue sarcomas ref

79 ogue that binds to serum albumin in vivo and is approved for once-daily treatment of diabetes as well

80 As these drugs have been approved for other clinical indications, they are n

81 Although interferon-free regimens are approved for patients co-infected with HIV and genot

82 KIs (gefitinib, erlotinib, and afatinib) has been approved for patients harbouring exon 19 deletions

83 trategies, and only one systemic therapy has been approved for patients with advanced tumors.

84 an oral inhibitor of Bruton tyrosine kinase, is approved for patients with mantle cell lymphoma (MCL)

85 n two placebo-controlled phase 3 trials, and is approved for patients with metastatic castration-resi

86 The sinus node inhibitor ivabradine was approved for patients with heart failure (HF) after

87 This drug was approved for patients with multiple myeloma who have

88 cule derived from Chinese herb gamboges, has been approved for Phase II clinical trial for cancer the

89 ers of CKD have been reported, but none have been approved for preclinical or clinical use.

90 No treatments have been approved for primary progressive multiple sclerosis

91 ical candidates, only a handful of adjuvants are approved for prophylactic vaccination of humans.

92 after surgery, but available only in Europe) are approved for prophylaxis in patients undergoing majo

93 Posaconazole has been approved for prophylaxis in HSCT.

94 Ustekinumab is approved for psoriasis and psoriatic arthritis treatm

95 PDE5Is are approved for pulmonary arterial hypertension, given

96 Rucaparib is approved for recurrent ovarian cancers with germline

97 Lenalidomide is approved for red blood cell (RBC) transfusion-depende

98 a once-a-day tablet formulation has recently been approved for reducing ethanol intake in alcoholic s

99 K kinase inhibitors crizotinib and ceritinib are approved for relapsed ALK(+) NSCLC, but acquired res

100 in, belinostat, and brentuximab vedotin have been approved for relapsed and refractory peripheral T-c

101 Telaprevir (TVR) has been approved for response-guided-therapy (RGT) of chron

102 In fact, B cell depletion with rituximab is approved for rheumatoid arthritis patients, and clini

103 t against influenza virus, yet few adjuvants are approved for routine use.

104 However, to date, no probe has been approved for routine imaging of cell death in the c

105 If this drug is approved for routine clinical use in patients with sc

106 A new drug application has been approved for SAHA (vorinostat) treatment of cutaneo

107 Rapalogs are approved for selected cancer types, including kidney

108 From 1995 onward, nine indications were approved for seven anticancer products based at lea

109 DNA demethylating agents are approved for some blood malignancies and are under a

110 widely used anticonvulsant that has recently been approved for stabilization of manic episodes in pat

111 se targeting the VEGF-A/VEGFR2 pathway, have been approved for subsets of solid tumors.

112 ge, an implantable topical antibiotic agent, is approved for surgical implantation in 54 countries.

113 As everolimus is approved for tamoxifen-resistant or relapsing estroge

114 mpairment (MCI) and AD, and therefore it has been approved for testing in clinical trials beginning i

115 amycin analogs, temsirolimus and everolimus, are approved for the treatment of advance renal cell car

116 uggest that mTORC1 inhibitors, many of which are approved for the treatment of certain cancers, shoul

117 Currently, 2 NA inhibitors are approved for the treatment of influenza in children.

118 lthough serotonin reuptake inhibitors (SRIs) are approved for the treatment of obsessive-compulsive d

119 Purpose Bevacizumab regimens are approved for the treatment of recurrent glioblastoma

120 Plasma-derived or recombinant C1INH products are approved for the treatment of such angioedema attack

121 The latest drug to be approved for the treatment of irritable bowel syndrom

122 olecule inhibitor of EGFR kinase function to be approved for the treatment of nonsmall cell lung canc

123 imumab, is the first new drug in 50 years to be approved for the treatment of SLE.

124 The following three TKIs have been approved for the management of advanced disease: im

125 Five medications have been approved for the management of obesity, but data on

126 estrogen receptor modulator (SERM) that has been approved for the prevention and treatment of postme

127 ta) that acts directly on the receptor--have been approved for the prevention of stroke and myocardia

128 No therapeutic agent has been approved for the prevention or treatment of this di

129 e scarce, except for cyclosporine, which has been approved for the therapy of severe AD.

130 hil elastase (NE) inhibitor, Sivelestat, has been approved for the treatment of acute lung injury ass

131 Inhaled iloprost has been approved for the treatment of adults with PAH, but

132 Five oral agents have been approved for the treatment of chronic hepatitis B,

133 Five oral antiviral agents have been approved for the treatment of chronic hepatitis B.

134 s a new and unique antianginal drug that has been approved for the treatment of chronic stable angina

135 Fidaxomicin has recently been approved for the treatment of Clostridium difficile

136 sine kinase inhibitor, sunitinib malate, has been approved for the treatment of imatinib-resistant ga

137 ture infections (SSSIs), and dalbavancin has been approved for the treatment of moderate to severe SS

138 tabine (DAC) and 5-azacitidine have recently been approved for the treatment of myelodysplastic syndr

139 cule inhibitor of the JAK kinases, which has been approved for the treatment of myelofibrosis, a rare

140 The antiangiogenic agent bevacizumab has been approved for the treatment of non-small cell lung c

141 oved agents that target the VHL pathway have been approved for the treatment of patients with advance

142 at doses well tolerated by patients and has been approved for the treatment of patients with cutaneo

143 uximab is an EGFR-blocking antibody that has been approved for the treatment of patients with head an

144 ly, the S1P analogue Fingolimod (FTY720) has been approved for the treatment of patients with relapsi

145 tiuxetan and tositumomab, respectively) have been approved for the treatment of refractory low-grade

146 in represents one such ADC that has recently been approved for the treatment of relapsed Hodgkin and

147 ) is a PI3Kdelta inhibitor that has recently been approved for the treatment of several hematological

148 (nAChRs) and full agonist for a7 nAChRs, has been approved for the treatment of smoking cessation.

149 dermal growth factor receptor therapies have been approved for the treatment of solid tumors.

150 mide, bortezomib, and lenalidomide have each been approved for the treatment of this disease by targe

151 of glucagon-like peptide 1 (GLP-1), and has been approved for the treatment of type 2 diabetes (T2D)

152 ht heparin in randomized clinical trials and is approved for the prevention and treatment of venous t

153 Tamoxifen is approved for the reduction of breast cancer risk, and

154 industrial source of ingenol mebutate, which is approved for the treatment of actinic keratosis, a pr

155 Although nesiritide is approved for the treatment of acute decompensated hea

156 Pazopanib, an oral angiogenesis inhibitor, is approved for the treatment of advanced renal cell car

157 Acamprosate is approved for the treatment of alcoholism, but its mec

158 Erlotinib is approved for the treatment of all patients with advan

159 antitumor Abs, including trastuzumab, which is approved for the treatment of breast cancer with HER2

160 an analgesic, and its topical administration is approved for the treatment of certain pain conditions

161 It is approved for the treatment of cutaneous T-cell lympho

162 th no need for pharmacokinetic boosting that is approved for the treatment of HIV-1 infection.

163 It is approved for the treatment of invasive aspergillosis

164 Vismodegib is approved for the treatment of locally advanced and me

165 The androgen receptor inhibitor enzalutamide is approved for the treatment of metastatic castration-r

166 -methyl-d-aspartate receptor antagonist that is approved for the treatment of moderate to severe Alzh

167 nd CD86, blocking interaction with CD28, and is approved for the treatment of moderate to severe rheu

168 e) is a reversible proteasome inhibitor that is approved for the treatment of multiple myeloma (MM).

169 d potent inhibitor of the 26S proteasome and is approved for the treatment of multiple myeloma.

170 TY720, a drug that targets S1P receptors and is approved for the treatment of multiple sclerosis, cau

171 5-aza-2'-deoxycytidine (DAC) is approved for the treatment of myelodysplastic syndrom

172 A polyethylene glycol-modified form of G-CSF is approved for the treatment of neutropenias.

173 Osimertinib is approved for the treatment of non-small-cell lung can

174 ne conductance regulator (CFTR) potentiator, is approved for the treatment of patients with cystic fi

175 Bevacizumab is approved for the treatment of patients with progressi

176 lalisib, a selective inhibitor of PI3Kdelta, is approved for the treatment of patients with relapsed

177 Pemetrexed in combination with cisplatin is approved for the treatment of pleural mesothelioma an

178 ) possesses anti-inflammatory properties and is approved for the treatment of psoriasis and multiple

179 Bevacizumab is approved for the treatment of recurrent glioblastoma,

180 ntibody-drug conjugate, brentuximab vedotin, is approved for the treatment of relapsed, refractory Ho

181 PDT is approved for the treatment of several cancers; howeve

182 vates silenced gene expression in cancer and is approved for the treatment of the myelodysplastic syn

183 The microcantilever biosensor was approved for the detection of phenytoin in solutions

184 obtained, and informed consent documentation was approved for the study protocol.

185 As such, synthetic BNP, nesiritide, was approved for the treatment of acutely decompensated

186 In 1995 fasudil was approved for the treatment of cerebral vasospasm, an

187 Duloxetine was approved for the treatment of chronic knee pain due

188 Recently, the first HDACi was approved for the treatment of cutaneous T cell lymph

189 Denileukin diftitox was approved for the treatment of cutaneous T-cell lymph

190 bral vasospasm, and more recently, ripasudil was approved for the treatment of glaucoma in 2014.

191 Bedaquiline is a new antibiotic that was approved for the treatment of multidrug-resistant (M

192 Lenalidomide was approved for the treatment of transfusion-dependent

193 ntibodies against IL-6 and its receptor have been approved for therapeutic intervention or are in adv

194 Currently, three PIs have been approved for therapy of chronic hepatitis C, and se

195 rugs are in advanced clinical development to be approved for this disease.

196 rbidity and mortality; however, no treatment is approved for this indication.

197 The Edwards SAPIEN valve was approved for transcatheter aortic valve implantation

198 Because rapamycin analogues are approved for treating other types of human malignanc

199 protein 1 (PD-1) and its ligand PD-L1, have been approved for treating human cancers with durable cl

200 demonstrated efficacy in clinical trials and is approved for treating ALS.

201 egy in the treatment of various diseases and is approved for treating hematological malignancies.

202 Activated factor VII is approved for treating hemophilia patients with autoan

203 5-HT2B and 5-HT2A agonist activities, which is approved for treating obesity.

204 Intravenous prostacyclin is approved for treating pulmonary arterial hypertension

205 Several testosterone-replacement therapies are approved for treatment and should be selected accord

206 lthough passive immunotherapy with these Abs are approved for treatment of advanced breast cancer, a

207 Several targeted drugs are approved for treatment of patients with metastatic r

208 No drugs are approved for treatment of premature ejaculation.

209 Glucagon-like peptide-1 (GLP-1) analogs are approved for treatment of type 2 diabetes and are in

210 GLP-1 analogs are approved for treatment of type 2 diabetes and are un

211 merase (PARP) inhibitor (PARPi) olaparib has been approved for treatment of advanced ovarian cancer a

212 Four drugs have been approved for treatment of and prophylaxis against i

213 Compound 29 has recently been approved for treatment of chronic HCV infection in

214 fosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus

215 A protease inhibitor telaprevir has recently been approved for treatment of genotype 1 chronic HCV in

216 combination of ledipasvir and sofosbuvir has been approved for treatment of genotype 1 hepatitis C vi

217 Sofosbuvir-containing regimens have been approved for treatment of hepatitis C virus (HCV) i

218 nificance, no specific antiviral agents have been approved for treatment of HMPV infection.

219 aserod, a 5-HT(4) partial agonist, which has been approved for treatment of irritable bowel syndrome

220 ary diseases such as haemophilia B, and have been approved for treatment of lipoprotein lipase defici

221 i-derived sphingosine homologue, FTY720, has been approved for treatment of multiple sclerosis.

222 wo of them (azacytidine and decitabine) have been approved for treatment of myelodysplastic syndromes

223 D20, B-cell-specific mAb rituximab (RTX) has been approved for treatment of non-Hodgkin's B cell lymp

224 an overview of medications that have not yet been approved for treatment of patients with IBS yet hav

225 r receptor (EGFR)-blocking antibody that has been approved for treatment of patients with metastatic

226 eceptors attenuate cardiac hypertrophy, have been approved for treatment of pulmonary hypertension, a

227 atacept, a humanized version of CTLA4Ig, has been approved for treatment of rheumatoid arthritis, pro

228 ctive PDE4 inhibitor Roflumilast-n-oxide has been approved for treatment of severe exacerbations of C

229 f renal cell carcinoma and two rapalogs have been approved for treatment of this malignancy.

230 y specific for tumor necrosis factor- alpha, is approved for treatment in patients with Inflammatory

231 thrombopoietin receptor agonist eltrombopag is approved for treatment of adults with chronic immune

232 Although trastuzumab is approved for treatment of advanced breast cancer, a n

233 Ranolazine, a NaCh blocker, is approved for treatment of angina.

234 The B2 receptor antagonist icatibant is approved for treatment of attacks of hereditary angio

235 Recombinant factor VIIa (rFVIIa) is approved for treatment of bleeding in patients who ha

236 utide, a long-acting GLP-1 receptor agonist, is approved for treatment of obesity; however, the mecha

237 h factor receptor (EGFR) inhibitor erlotinib is approved for treatment of pancreatic cancer but the o

238 ients with advanced basal cell carcinoma and is approved for treatment of patients with advanced basa

239 The antibody trastuzumab is approved for treatment of patients with HER2 (ERBB2)-

240 Phenylbutyric acid (PBA), which is approved for treatment of urea cycle disorders (UCDs)

241 e of the short-chain fatty acid butyrate and is approved for treatment of urea cycle disorders and pr

242 hasone intravitreal implant 0.7 mg (DEX 0.7) was approved for treatment of diabetic macular edema (DM

243 ylated interferon alfa-2b (PEG-IFN-alpha-2b) was approved for treatment of resected stage III melanom

244 Glucagon-like peptide-1 analogs are approved for type 2 diabetes mellitus; preclinical a

245 , several DPP IV inhibitors, the "gliptins", are approved for type 2 diabetes or are under clinical e

246 ays might have clinical applications if they are approved for use by the FDA.

247 the 30% range, and no antivirals or vaccines are approved for use for treatment and prevention of SFT

248 luenza vaccines propagated in cultured cells are approved for use in humans, but their yields are oft

249 Both drugs are approved for use in locally advanced BCC (laBCC), wi

250 These drugs are approved for use in patients with cardiovascular dis

251 oV diagnosis detect only certain strains and are approved for use in the United States only in epidem

252 Currently, no UTI vaccines are approved for use in the United States, and the devel

253 No effective antivirals or vaccines for RSV are approved for use in the United States; however, ther

254 for relapsed disease, although a few agents are approved for use in this setting.

255 ane production, dosages as high as 1300 mg/d are approved for use.

256 effective in the populations for which they are approved for use.

257 recommended that this combination medication be approved for use as PrEP in high-risk persons without

258 wth factor receptor antibody cetuximab, have been approved for use as single agents or in combination

259 New devices have recently been approved for use in adolescents, yet pediatricians

260 the last 15 years, several medications have been approved for use in alcohol dependence but have onl

261 Sacubitril/valsartan has been approved for use in heart failure (HF) with reduced

262 ting disease progression, no inhibitors have been approved for use in humans.

263 ombopoietin-receptor agonists (TPO-RAs) have been approved for use in immune thrombocytopenia (ITP) a

264 occal conjugate vaccine (PCV13) has recently been approved for use in immunocompromised adults.

265 Cetuximab is an anti-EGFR antibody that has been approved for use in oncology.

266 protein C (drotrecogin alfa [activated]) has been approved for use in patients with severe sepsis.

267 hough a number of useful anti-HIV drugs have been approved for use in patients, the problems associat

268 , a biologic targeting the IL-6 pathway, has been approved for use in rheumatoid arthritis and intere

269 e oligonucleotide against APOB have recently been approved for use in subjects with clinically diagno

270 summarizes the Fc fusion proteins that have been approved for use in the clinic and those that are c

271 NTBC has been approved for use in the treatment of type I tyrosin

272 ew products on the market, but more EOs have been approved for use in the United States than elsewher

273 Sacral nerve stimulation has been approved for use in treating urinary incontinence i

274 All of these therapies have been approved for use on the basis of relatively small,

275 FR-targeted therapies such as erlotinib have been approved for use without molecular testing, immunoh

276 cal trials, no vaccines or therapeutics have been approved for use.

277 ctive therapies for respiratory disease have been approved for use.

278 tal Artificial Heart (Syncardia, Tucson, AZ) is approved for use as a bridge-to-transplant or destina

279 the natural environment and its organic form is approved for use as a feed additive for animal produc

280 molecule that has antioxidant properties and is approved for use as an MRI contrast enhancer.

281 a first-in-class Hedgehog-pathway inhibitor, is approved for use in adults with advanced basal-cell c

282 ralong-acting, once-daily basal insulin that is approved for use in adults, adolescents, and children

283 gainst the epidermal growth factor receptor, is approved for use in colorectal cancer and squamous-ce

284 Doxorubicin (Dox) is approved for use in liposomal form for the treatment

285 an intravenous, reversible P2Y12 antagonist, is approved for use in patients undergoing percutaneous

286 eric IgG1 mAb directed against the EGFR that is approved for use in patients with colorectal and head

287 EBR/GZR is approved for use in patients with renal impairment an

288 , which continues to develop new technology, is approved for use in the United States.

289 Auranofin (Ridaura) is approved for use in treating rheumatoid arthritis, bu

290 The CCR5 antagonist maraviroc is approved for use in treatment-naive and treatment-exp

291 acute ischaemic stroke was alteplase, which is approved for use within 4.5 h after stroke onset in m

292 ssisted device, the daVinci surgical system, was approved for use in gynecology in April 2005, many p

293 iodegradable fluocinolone acetonide implant, was approved for use in noninfectious uveitis affecting

294 e acute lymphoblastic leukemia (ALL) blasts, was approved for use in patients with relapsed or refrac

295 Drotrecogin alfa (activated) was approved for use in severe sepsis in 2001 on the bas

296 In March 2017, dupilumab was approved for use in the treatment of atopic dermatit

297 ars in Europe, this antiepileptic medication was approved for use in the USA only 1 year ago because

298 alent meningococcal conjugate vaccine (MCV4) was approved for use.

299 NS3/4A PIs (PIs), telaprevir and boceprevir, were approved for use in combination with PegIFN/RBV for

300 luenza vaccines (LAIV and TIV, respectively) are approved for young children (>/= 24 months old for L